|Bid||2.9000 x 1100|
|Ask||3.1000 x 1400|
|Day's Range||2.8500 - 3.0300|
|52 Week Range||1.6500 - 10.8000|
|Beta (3Y Monthly)||3.46|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced the results of three key performance metrics that together demonstrate the continued growth and positive impact of the sales force’s expansion improving pathology sales performance. Precipio’s management team has established several key metrics that quantify pathology sales team performance and highlight areas of opportunity. The metrics highlighted above track conversions and trends across the sales pipeline to evaluate our success in attracting, retaining and growing “high-value” customers via trials and repeat orders.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its Second quarter 2019 corporate update call on Wednesday, August 21st at 5:00 PM ET, following its recent filing of its Form 10-Q on August 9th, 2019 and the release of its financial results for the second quarter ending June 30, 2019. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call.
This also provides the company with unencumbered-by-insurance reimbursement, high-margin revenues which contribute to growing both the top and bottom lines. Pursuant to Precipio’s strategic plan led by Chief Strategy Officer Ori Karev, the Company determined that the optimal approach to penetrating non-US markets is to first promote our proprietary technologies.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced the initiation of a second development project with H3 Biomedicine that will include the creation of a targeted gene panel. The panel would be used by H3 Biomedicine for their ongoing clinical development programs. H3 Biomedicine was launched in 2011 with an unprecedented $200 million funding commitment from Eisai, a leading global pharmaceutical company pharmaceuticals company, plus additional funding for clinical programs.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), provides an update to its shareholders. First, we would like to address the business activities surrounding our new products, IV-Cell and HemeScreen. Both IV-Cell and HemeScreen are proprietary to Precipio and have patents pending.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has entered into an exclusive subcontracting manufacturing agreement with diagnostics manufacturing company Novamed for the production of Precipio’s proprietary IV-Cell media for an initial term of 3 years. Novamed’s extensive experience providing various reagents to companies such as Thermo Fisher and Abbott Laboratories, as well as favorable business terms reached, were all key to its selection as Precipio’s choice manufacturer. The lengthy review and negotiation process was completed this week, following an extensive, in-depth technical, manufacturing and logistics due diligence, in which Precipio carefully evaluated Novamed’s capabilities to manufacture and deliver the IV-Cell media to Precipio’s specifications.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today provides shareholders with three of the key pathology performance metrics tracked by the company to ensure continuous growth of the business. The company’s revenues are comprised of two key components.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that, as previously stated, Ilan Danieli, Precipio’s CEO, has enrolled in a plan to purchase Precipio’s common stock on the open market in accordance with Rule 10b5-1 of the Securities and Exchange Act of 1934. Rule 10b5-1 allows officers and directors to enter into written, prearranged stock trading plans for the purpose of purchasing (or selling) company stock on the open market when they are in possession of material non-public information. Once established, officers and directors have no discretion over purchase or sales of stock under the plan and the pre-planned trades shall be executed as prescribed by the plan without regard for any subsequent material non-public information that the plan participant may receive.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that on May 15, 2019 the Company received a letter from Nasdaq informing the Company that it had regained compliance with the Bid Price Rule and the matter is now closed. The company's shares will continue to be traded on The Nasdaq Global Market under the symbol PRPO. “We are pleased with the confirmation from Nasdaq on our compliance, ensuring that our shareholders have stock that is traded on a reputable exchange such as Nasdaq,” said Ilan Danieli, Precipio’s Chief Executive Officer.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it is in the process of completing a trial of its Proprietary IV-Cell media with a significant laboratory (name undisclosed at this time). Upon successful completion of the study, Precipio and the laboratory shall continue their commercial discussions to become the lab’s provider of the IV-Cell media for ongoing clinical use within its cytogenetics laboratory. Upon the signing of the manufacturing agreement, Precipio will announce the name of the manufacturer to the market and commence production and supply of the media to its laboratory customers.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that yesterday, in accordance with established Nasdaq protocol, the company held a hearing regarding its recent steps undertaken by it in order to regain compliance with the minimum bid price of $1.00. The company presented a solid business plan before the Panel with strong growth prospects indicating to the Panel that we believe these measures will enable our share price to meet the requirements necessary to remain listed on the Nasdaq,” said Ilan Danieli, Precipio’s CEO.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will host a conference call on Monday, May 6th, 2019 at 5:00pm Eastern Time to review recent company and business events, and provide a corporate update. The conference call may be accessed by calling 1-844-695-5519 (international callers may dial 1-412-902-6760). All callers should ask for the Precipio Inc. conference call.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has signed a services contract with a health care management group serving several major hospitals based in Cairo, Egypt. Follow-on intended business collaborations will include the establishment of laboratory operations within Egypt that will license Precipio’s proprietary technologies to provide liquid biopsy testing using ICE-COLD PCR technology, and HemeScreen for hematologic molecular testing. In addition, once Precipio’s liquid biopsy and HemeScreen tests are available within Egypt, revenues will be substantially augmented from sales of Precipio’s tests.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-15 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. While the company’s share price has recently increased, it was not sufficient to regain compliance with the Nasdaq continued listing requirements, and therefore the company decided to effectuate the reverse split.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the launch of Precipio’s global pathology services. Similarly, in countries around the world there is the same need for access to the expertise provided by Precipio. Led by Ori Karev, Precipio's recently hired Chief Strategy Officer, Precipio has already launched discussions with leading hospitals, healthcare providers and regional health insurance carriers to discuss implementation of Precipio's model in their respective countries.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that Mr. Ori Karev has joined the company as its Chief Strategy Officer. Ori was formerly CEO of UnitedHealthcare Global, the International division of United Healthcare, the world’s largest health insurance provider. Under Ori’s leadership, UnitedHealthcare Global expanded its operations to more than 100 countries, employing more than 1,000 FTEs.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) will be hosting its 2018 year-end corporate update call on Monday, May 6 at 5:00 PM ET, following the expected filing on April 16 of its form 10-K and release of its financial results for the fiscal year ending December 31, 2018. The shareholder call will take place following the company’s completion of the necessary actions intended to regain compliance with its Nasdaq listing requirements relating to the bid price of minimum $1.00. In addition to the financial review of the year-end results, management will review the actions that led to its share price exceeding the $1.00 threshold required to regain compliance, and the company’s plans for continued share price appreciation.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced today that it is negotiating a definitive agreement with a manufacturer to produce its IV-Cell media. Over the past year, Precipio has been working to commercialize its patented IV-Cell media by offering the Research-Use Only (RUO) based media to large laboratory customers who offer cancer cytogenetics testing. As part of Precipio’s continuous effort to expand and improve the economics of our business, it became apparent that the best alternative for Precipio would be to identify a manufacturing partner to produce the media for those customers.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that Methodist Hospital, located in Memphis, TN, has selected Precipio’s HemeScreen assay for use in its molecular hematology testing laboratory. Methodist was previously sending out these tests to a local laboratory, and was experiencing an average turn-around-time (TAT) of 2-4 weeks. Methodist has elected to send their patient samples to Precipio for the HemeScreen assay, where they will be guaranteed an average of 2-4 days TAT.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has received the expected delisting determination from Nasdaq Staff. The Company has subsequently filed a request for a hearing before the Nasdaq Hearings Panel (the "Panel"), as management believes that it has strong basis for requesting the appeal. The process involves the Company requesting a compliance hearing within 7 days from the receipt of the delisting notification.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), issues the following letter from CEO Ilan Danieli. The management team’s goal to protect and preserve shareholder value remains in focus at all times. As we face the deadline to achieve compliance with the US$1.00 minimum bid price requirement by March 25, 2019, management and the board continue to strive to either avoid a reverse split, or at least to minimize the reverse split ratio.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it continues to receive both new and repeat business from customers in Japan for its ICP liquid biopsy enrichment technology. Recently, Kyorin University Hospital in Tokyo, placed its third order for Precipio’s ICP assay.
Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), will host a conference call on Thursday, February 21st, 2019 at 4:30pm to review financial results and provide a corporate update. During the call, as a recap to existing investors, and an introduction to new investors, management will also review the company’s business model and provide an overview of the product and services the company offers. Lastly, management will address the concerns of shareholder value, and the plans to achieve a recovery of the company’s stock.
Furthermore, fourth quarter financials demonstrated continuous movement towards the company’s target of profitability. Key metrics demonstrate the company’s ongoing improvement of its financial performance, with YoY revenue growth alongside the reduction of costs, to ensure that its continuous growth translates into bottom-line results. The company implemented substantial cost-cutting measures in the second half of 2018, the results of which have created a positive impact on the company’s fourth quarter financials.
Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced a recent radio show interview of Ilan Danieli, Precipio’s CEO, on the New York Nassau Community College Radio station. The interview addressed the problem of cancer misdiagnosis, offered thoughts on ways patients can become aware of this problem, and discussed potential options patients and their physicians have to battle this problem. On his show “My Hometown”, veteran radio talk show host Bill Horan interviewed Ilan Danieli to discuss the scope of the problem of cancer misdiagnosis, some of the causes of this phenomenon, and the work the team at Precipio is doing to help physicians and their patients obtain an accurate diagnosis.